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Unusual Occurrence of Intestinal Pseudo Obstruction in a 
Patient with Maternally Inherited Diabetes and Deafness 
(MIDD) and Favorable Outcome with Coenzyme Q10
ABSTRACT
Maternally inherited diabetes and deafness (MIDD) has been related to an A 
to G transition in the mitochondrial tRNA Leu (UUR) gene at the base pair 
3243. This subtype of diabetes is characterized by maternal transmission, 
young age at onset and bilateral hearing impairment. Besides diabetes and 
deafness, the main diagnostic features, a wide range of multisystemic symp-
toms may be associated with the A3243G mutation. Organs that are most 
metabolically active, such as muscles, myocardium, retina, cochlea, kidney 
and brain are frequently affected. Gastrointestinal tract symptoms are also 
common in patients with mitochondrial disease and constipation and diar-
rhea are the most frequent manifestations. However, there are few prior re-
ports of intestinal pseudo obstruction in MIDD patients. Here we report the 
case of a patient with MIDD associated with the mtDNA A3243G mutation 
who developed chronic intestinal pseudo obstruction, and the introduction of 
Coenzyme Q10 as adjunctive therapy led to a solution of the pseudo obstruc-
tion. (Arq Bras Endocrinol Metab 2008; 52/8:1345-1349)
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RESUMO
Pseudo-Obstrução Intestinal em Paciente com Diabetes Mitocondrial 
que Apresentou Boa Resposta ao Tratamento Adjunto com Coenzima 
Q10.
Diabetes mitocondrial ou diabetes e surdez de herança maternal (MIDD, acrôni-
mo de maternally inherited diabetes and deafness) é freqüentemente associado 
à mutação mitocondrial A3243G. Esse subtipo de diabetes é caracterizado por 
transmissão materna, disacusia neuro-sensorial bilateral e idade precoce de 
aparecimento. Além do diabetes e da surdez, principais características diagnós-
ticas, outros sintomas em diferentes órgãos podem também associar-se à muta-
ção A3243G. Os órgãos que são metabolicamente mais ativos, tais como 
músculos, miocárdio, retina, cóclea, rim e cérebro, são freqüentemente afetados. 
Sintomas do trato gastrintestinal também são comuns em pacientes com doen-
ça mitocondrial, sendo diarréia e obstipação as manifestações mais freqüentes. 
Entretanto, há poucos relatos de pseudo-obstrução intestinal em portadores de 
diabetes mitocondrial. Este relato descreve o caso de uma paciente com diabe-
tes mitocondrial que apresentou pseudo-obstrução intestinal e que com a in-
trodução de coenzima Q10, como terapia adjunta, teve resolução o quadro. (Arq 
Bras Endocrinol Metab 2008; 52/8:1345-1349)
Descritores: Diabetes mitocondrial; MIDD; Coenzima Q10; Pseudo-obstrução 
intestinal
INTRODUCTION
Maternally-inherited diabetes and deafness (MIDD) or mitochondrial diabetes mellitus (OMIM 520000), in the large majority of the cases, 
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has been related to an A to G transition in the mito-
chondrial tRNA Leu (UUR) gene at the base pair 3243 
(1-4). This subtype of diabetes is characterized by ma-
ternal transmission, as the name suggests, young age at 
onset and bilateral hearing impairment (5). Some pa-
tients become rapidly dependent on insulin treatment 
and might be diagnosed as type 1 diabetes, while others, 
can be managed with a diet or oral hypoglycemic agents 
for a variable time period and are often classifi ed as type 
2 diabetes. However, insulinopenia is progressive and 
some years after the onset of diabetes, most patients 
will need insulin therapy.
The underlying defect in mitochondrial diabetes is 
a progressive impairment of insulin secretion (6-8). 
The molecular mechanism by which the A3243G mu-
tation affects insulin secretion may involve ATP genera-
tion, since high plasma glucose concentration, via 
glycolysis and mitochondrial metabolism, leads to high 
ATP/ADP ratios within the cell. This ratio is sensed by 
subunits of ATP-sensitive potassium channels, closing 
them, which results in membrane depolarization. This 
process triggers the opening of voltage-gated calcium 
channels, causing calcium infl ux and insulin release. 
Thus, any change in the biochemical pathway linking 
glucose uptake and ATP generation can possibly impair 
the effi ciency by which glucose stimulates insulin secre-
tion. Furthermore, mitochondrial diabetes does show a 
pronounced age – dependent deterioration of pancrea-
tic function indicating involvement of additional pro-
cesses.
The prevalence of MIDD in diabetic population 
accounts for 0.2-3%, depending on the ethnic back-
ground (9-11). In samples of our population previous 
studies showed a frequency of 0.4% (12,13).
Besides diabetes and deafness, the main diagnostic 
features, a wide range of multisystemic symptoms may 
be associated with the A3243G mutation. Organs that 
are most metabolically active, such as muscles, myocar-
dium, retina, cochlea, kidney and brain are frequently 
affected. Gastrointestinal tract symptoms are also fre-
quent in patients with mitochondrial disease. Gastroin-
testinal dysmotility, including diarrhea and 
pseudo-obstruction, is the most prominent manifesta-
tion of MNGIE (Mitochondrial NeuroGastroIntestinal 
Encephalomyopathy), an autosomal gene defect that 
induces multiple mtDNA deletions (14). In another 
mitochondrial disease, MELAS (myopathy, encephalo-
pathy, lactic acidosis and stroke-like episodes), ischae-
mic colitis, chronic diarrhea and intestinal obstruction 
have been described before (15-18). In MIDD, Nar-
bonne et al found constipation, diarrhea, or both in 
88% of patients bearing the A3243G mutation (19).
In clinical practice, constipation in a diabetic pa-
tient is treated conservatively with the usual methods 
using bulk agents and stool softeners. If these agents 
fail, laxatives used prudently can be quite helpful. Cisa-
pride was shown to have prokinetic properties in some, 
but not all patients with idiopathic or diabetic constipa-
tion. Not frequently, colonic dysfunction in diabetic 
patients may lead to more severe colonic disorders as a 
marked sigmoid dilatation.
Coenzyme Q10 (CoQ10) plays a central role in the 
mitochondrial respiratory chain by acting as an electron 
carrier. In addition, Co Q10 has also antioxidant and 
membrane stabilizing properties. There are previous 
reports showing benefi cial effects of CoQ10 on some 
neuromuscular symptoms, prevention of progressive 
insulin secretory defect, exercise intolerance, hearing 
loss and myocardial dysfunction in MIDD patients 
(20-23).
Here we report the unusual occurrence of intesti-
nal pseudo obstruction in a patient with a MIDD and 
the therapeutic usefulness of Coenzyme Q10.
SUBJECTS AND METHODS
A 47-year-old woman with sensorial hearing loss and 
diabetes presented with abdominal distension and 
constipation.
Molecular analysis of A3243G mutation 
Total DNA was extracted from peripheral blood leu-
kocytes using a commercial kit (Puregene DNA Isola-
tion Kit, Gentra System, Minneapolis, MN, USA). 
Detection of the 3243 A-to-G transition in the mito-
chondrial tRNA Leu (UUR) gene was carried out by 
polymerase chain reaction A3243G (PCR), Apa I di-
gestion, and acrylamide gel electrophoresis. Bands were 
visualized by ethidium bromide staining. 
RESULTS 
Case Report
A 47-year-old diabetic woman presented with recurrent 
pain and abdominal distention and severe constipation, 
who had already prompted previous hospitalizations. 
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Surgical treatment had already been proposed due to 
non-response to usual clinical management.
She was diagnosed with diabetes mellitus at the age 
of 11 years and had been treated with insulin since 
then. Progressive bilateral sensorineural hearing loss 
developed at age 27 and required cochlear implant. She 
also developed proliferative diabetic retinopathy requi-
ring laser photocoagulation and end-stage renal failure, 
being on hemodialysis treatment for one year.
She had a family history of diabetes mellitus and 
hearing loss in her mother, two sisters and a nephew. 
Her mother had a history of abdominal distension and 
died due to clinical complications related to an intesti-
nal rupture. 
Molecular genetic analysis was conducted in the 
patient and available relatives. The presence of the he-
teroplasmic point mutation at position 3243 (A3243G) 
of mtDNA was found in the patient, her sister and ne-
phew, which confi rmed the diagnosis of MIDD. We 
were told that the proband’s daughter had hearing im-
pairment and glucose intolerance but we could not 
examine her (Figure 1).
Figure 1. Pedigree of the studied family. The individuals with 
diabetes mellitus and hearing impairment are represented 
with fi lled symbols. Arrow indicates the proband. + denotes 
presence of A3243G mutation. NT = not tested.
The patient BMI was 22.1 kg/m2 and her HbA1c 
level was 10.0% (normal range: 4.0-6.1%). Sensory and 
motor polyneuropathy were detected by neurological 
examination and electromyography. Intestinal and co-
lon transit time showed diffuse bowel dilatation, mega-
duodenum and colonic inertia. CT scan showed diffuse 
stomach and intestinal dilatation without stenosis (Fi-
gure 2). Based on these fi ndings, the diagnosis of intes-
tinal pseudo occlusion was made. Despite of treatment 
with prokinet and antiemetics agents, the symptoms 
persisted. After this, Co Q10 100 mg/day was added 
to the treatment. She responded well and her symp-
toms improved. Thereafter, after a three year follow-
up, she experienced no gastrointestinal symptoms. 
Figure 2. Abdominal CT scan shows distended bowel loops 
with air-fl uid levels, without stenosis, suggesting intestinal 
pseudo-obstruction.
DISCUSSION
Here we report the case of a patient with MIDD asso-
ciated with the mtDNA A3243G mutation who deve-
loped chronic intestinal pseudo obstruction and 
responded well to the treatment with Coenzyme Q10.
MIDD, although a rare condition, is important to 
be correctly diagnosed since it has implications on the-
rapeutics, screening of associated manifestations and 
family screening. It appears to be a decreased prevalen-
ce of diabetic retinopathy in MIDD. Guillausseau el al 
found that despite a mean duration of diabetes of 12 
years, only 8% of patients exhibited diabetic retinopathy 
(24). Similar fi ndings were obtained by Holmes-Walker 
and cols. (25). In contrast, the prevalence of nephropa-
thy is high. Massin et al in a French multicenter study 
found renal dysfunction in 53.7% of MIDD patients 
compared with 28.5% in diabetic controls without 
A3243G mutation (26). The most prevalent fi nding in 
kidney biopsies is focal segmental glomerulosclerosis 
(24,27). These fi ndings suggested that a specifi c mito-
chondrial defect, rather than diabetic nephropathy, may 
be responsible for renal impairment in MIDD. Our pa-
tient, during the evolution of MIDD, developed end-
stage renal disease. Since she had longstanding diabetes, 
poor metabolic control and severe diabetic retinopathy, 
we can infer that the primary cause of her renal disease 
was a diabetic nephropathy. However, specifi c mito-
chondrial kidney disease cannot be excluded.
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Gastrointestinal tract symptoms are frequent in 
MIDD patients. Narbonne et al found that constipa-
tion was the most frequent manifestation, but diarrhea, 
nausea or vomiting and abdominal pain were also found 
(19). However, there are few prior reports of intestinal 
pseudo obstruction in MIDD patients (19,28). Pseudo 
intestinal obstruction is a severe condition characteri-
zed by disabling and potentially life-threatening com-
plications over time (29). Accordingly, Narbonne et al 
reported the case of a fatal intestinal pseudo obstruc-
tion in a patient with severe MIDD (19) and Hiel et al 
in a patient with MELAS (30). The etiology of this 
condition in mitochondrial diseases is unclear. The ab-
normality can be due to either a miogenic or neuroge-
nic origin, or both (14,28,31,32). In the present 
pedigree, the proband carrying the mtDNA A3243G 
mutation developed intestinal pseudo obstruction and 
her mother, an obligatory carrier of the mutation, had 
symptoms that resemble the same condition and resul-
ted in her death, illustrating the familial occurrence of 
intestinal pseudo obstruction.  
Coenzyme Q10 acts as an electron carrier of the 
respiratory chain in mitochondria and  has also antioxi-
dant and membrane stabilizing properties. Shimotake 
and cols. (17) reported the use of intravenous adminis-
tration of Co Q10 in MELAS children who developed 
intestinal pseudo obstruction, resulting in gradual re-
covery in the following days. However, there are also 
reports of the occurrence of intestinal pseudo obstruc-
tion in patients already using Co Q10 (18,19,33). In 
our patient the introduction of Co Q10 as adjunctive 
therapy led to a resolution of the pseudo obstruction.
In summary, here we report the case of diabetic 
patient diagnosed as MIDD associated to mitochon-
drial DNA A3243G mutation who developed chronic 
intestinal obstruction and responded well to the treat-
ment with Coenzyme Q10. Intestinal pseudo obstruc-
tion is a rare but severe condition and Coenzyme Q10 
may be an adjunctive therapy for this condition in 
MIDD patients.
No potencial confl ict of interest relevant to this article was re-
ported. 
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